Japan Nuclear Imaging Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Japan Nuclear Imaging Market is segmented by Product (Equipment and Radioisotope) and Application (SPECT Applications and PET Applications). The market provides the value (in USD million) for the above-mentioned segments.

Japan Nuclear Imaging Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Japan Nuclear Imaging Market Size

View Global Report
Japan Nuclear Imaging Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
Market Size (2025) USD 340.23 Million
Market Size (2030) USD 425.00 Million
CAGR (2025 - 2030) 4.55 %

Major Players

Japan Nuclear Imaging Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Japan Nuclear Imaging Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Japan Nuclear Imaging Market Analysis

The Japan Nuclear Imaging Market size is estimated at USD 340.23 million in 2025, and is expected to reach USD 425.00 million by 2030, at a CAGR of 4.55% during the forecast period (2025-2030).

Certain factors that are driving the market growth include the rise in prevalence of cancer and cardiac disorders, increase in technological advancements, growth in the applications of nuclear medicine and imaging.

After being ranked the topmost cause of life-loss in the last century, stroke is now the third-ranked cause of death in Japan, following cancer and heart disease. According to the 2018 article, 'Lifestyle and cardiovascular disease in Japan', the recent trend of rising CHD (coronary heart disease) prevalence among the urban population is a cause for serious concern, as a potential source of forthcoming problems for public health as well as clinical practice in Japan. Moreover, due to the association between lifestyle and CVD (cardiovascular disease), higher sodium, lower calcium, and lower animal protein content in the diet, along with higher alcohol consumption, may account for the higher prevalence of hypertension and higher risk of stroke in the Japanese population than for western population at same BMI levels. According to the latest OECD data, in Japan, patients with end-stage kidney failure (ESKF), often caused by diabetes and hypertension, are the highest in the OECD at 238 per 100,000 population while the average is 101. Thus, the increasing prevalence of cancer, along with certain cardiovascular diseases, is expected to propel the growth of the nuclear imaging market in Japan.

Japan Nuclear Imaging Industry Overview

The Japanese Nuclear Imaging market is moderately competitive and consists of a few major players. Some of the key companies in the market include ATOX CO. Ltd, Bracco Imaging SpA, CANON INC., Fujifilm (FUJIFILM Toyama Chemical Co. Ltd), GE Healthcare, IBA Radiopharma Solutions, and JFE Engineering Corporation.

Japan Nuclear Imaging Market Leaders

  1. Bracco Imaging SpA

  2. CANON INC.

  3. Fujifilm (FUJIFILM Toyama Chemical Co. Ltd)

  4. GE Healthcare

  5. ATOX

  6. *Disclaimer: Major Players sorted in no particular order
Japan Nuclear Imaging Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Japan Nuclear Imaging Market News

  • Oct 2022: The IAEA redesignated National Institutes for Quantum Science and Technology (QST) as a Collaborating Centre until 2026 for radiation oncology, nuclear medicine and molecular imaging, dosimetry, and science technology and society.
  • Aug 2022: PeptiDream Inc., a Japan-based biopharmaceutical company, expanded its strategic partnership with RayzeBio Inc. to discover and develop peptide-radioisotope (RI) conjugates for use as radiopharmaceutical therapeutics. Under the terms of the agreement, RayzeBio grants PeptiDream an option to attain development and commercialization rights in Japan for the joint peptide-RI programs.
  • Jan 2021: Fuzionaire Radioisotope Technologies K.K. entered into a feasibility study agreement with Nihon Medi-Physics Co. Ltd, a Japan-based radiopharmaceutical company, to develop and commercialize Fuzionaire Dx's radiopharmaceutical technologies in Japan.

Japan Nuclear Imaging Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Prevalence of Cancer and Cardiac Disorders
    • 4.2.2 Increase in Technological Advancements
    • 4.2.3 Growth in the Applications of Nuclear Medicine and Imaging
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Techniques
    • 4.3.2 Short Half-life of Radiopharmaceuticals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 Product
    • 5.1.1 Equipment
    • 5.1.2 Radioisotope
    • 5.1.2.1 SPECT Radioisotopes
    • 5.1.2.1.1 Technetium-99m (TC-99m)
    • 5.1.2.1.2 Thallium-201 (TI-201)
    • 5.1.2.1.3 Gallium (Ga-67)
    • 5.1.2.1.4 Iodine (I-123)
    • 5.1.2.1.5 Other SPECT Radioisotopes
    • 5.1.2.2 PET Radioisotopes
    • 5.1.2.2.1 Fluorine-18 (F-18)
    • 5.1.2.2.2 Rubidium-82 (RB-82)
    • 5.1.2.2.3 Other PET Radioisotopes
  • 5.2 Application
    • 5.2.1 SPECT Applications
    • 5.2.1.1 Orthopedics
    • 5.2.1.2 Thyroid
    • 5.2.1.3 Cardiology
    • 5.2.1.4 Other SPECT Applications
    • 5.2.2 PET Applications
    • 5.2.2.1 Oncology
    • 5.2.2.2 Cardiology
    • 5.2.2.3 Neurology
    • 5.2.2.4 Other PET Applications

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 ATOX CO. Ltd
    • 6.1.2 Bracco Imaging SpA
    • 6.1.3 CANON INC.
    • 6.1.4 Fujifilm (FUJIFILM Toyama Chemical Co. Ltd)
    • 6.1.5 GE HEALTHCARE
    • 6.1.6 IBA Radiopharma Solutions
    • 6.1.7 JFE Engineering Corporation
    • 6.1.8 Koninklijke Philips NV
    • 6.1.9 Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd)
    • 6.1.10 Siemens Healthineers
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Japan Nuclear Imaging Industry Segmentation

As per the scope of the report, nuclear medicine imaging procedures are non-invasive, with the exception of intravenous injections, and are usually painless medical tests that help physicians diagnose and evaluate medical conditions. These imaging scans use radioactive materials called radiopharmaceuticals or radiotracers. These radiopharmaceuticals are used in diagnosis and therapeutics. They are small substances that contain a radioactive substance that is used in the treatment of cancer and cardiac and neurological disorders. 

The Japanese Nuclear Imaging Market is Segmented by Product (Equipment and Radioisotope (SPECT Radioisotopes (Technetium-99m (TC-99m), Thallium-201 (TI-201), Gallium (Ga-67), Iodine (I-123), and Other SPECT Radioisotopes) and PET Radioisotopes (Fluorine-18 (F-18), Rubidium-82 (RB-82), and Other PET Radioisotopes), Application (SPECT Applications (Orthopedics, Thyroid, Cardiology, and Other SPECT Applications) and PET Applications (Oncology, Oncology, Neurology, and Other PET Applications). The report offers the value (in USD million) for the above segments.

Product Equipment
Radioisotope SPECT Radioisotopes Technetium-99m (TC-99m)
Thallium-201 (TI-201)
Gallium (Ga-67)
Iodine (I-123)
Other SPECT Radioisotopes
PET Radioisotopes Fluorine-18 (F-18)
Rubidium-82 (RB-82)
Other PET Radioisotopes
Application SPECT Applications Orthopedics
Thyroid
Cardiology
Other SPECT Applications
PET Applications Oncology
Cardiology
Neurology
Other PET Applications
Need A Different Region or Segment?
Customize Now

Japan Nuclear Imaging Market Research FAQs

How big is the Japan Nuclear Imaging Market?

The Japan Nuclear Imaging Market size is expected to reach USD 340.23 million in 2025 and grow at a CAGR of 4.55% to reach USD 425.00 million by 2030.

What is the current Japan Nuclear Imaging Market size?

In 2025, the Japan Nuclear Imaging Market size is expected to reach USD 340.23 million.

Who are the key players in Japan Nuclear Imaging Market?

Bracco Imaging SpA, CANON INC., Fujifilm (FUJIFILM Toyama Chemical Co. Ltd), GE Healthcare and ATOX are the major companies operating in the Japan Nuclear Imaging Market.

What years does this Japan Nuclear Imaging Market cover, and what was the market size in 2024?

In 2024, the Japan Nuclear Imaging Market size was estimated at USD 324.75 million. The report covers the Japan Nuclear Imaging Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Japan Nuclear Imaging Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Japan Nuclear Imaging Devices Industry Report

Statistics for the 2025 Japan Nuclear Imaging market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Japan Nuclear Imaging analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.